CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 53 enrolled
Drug / intervention
LY3451838 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03692949
NCT03692949Phase 1Completed
CompareCT.gov

A Safety, Tolerability, and Pharmacokinetics Study of LY3451838 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Oct 2, 2018·Updated Sep 11, 2025

In Brief

A Phase 1 clinical trial evaluating LY3451838 and Placebo for Healthy. Completed, enrolled 53 participants across 1 site.

Detailed Summary

The study has two parts. In Part A, single increasing doses of LY3451838 will be administered intravenously (into a vein). In Part B, a single dose of LY3451838 will be administered subcutaneously (just under the skin).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 2, 2018
Enrollment StartDec 11, 2018
Primary CompletionFeb 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.8 years ago

Interventions

LY3451838drug

Administered IV Part A

LY3451838drug

Administered IV Part A

LY3451838drug

Administered IV Part A

LY3451838drug

Administered IV Part A

LY3451838drug

Administered IV Part A

LY3451838drug

Administered IV Part A

LY3451838drug

Administered SC Part B

Placebodrug

Administered IV in Part A and SC in Part B